Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.MethodsConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Har...
Saved in:
Published in | Rheumatic & musculoskeletal diseases open Vol. 9; no. 3; p. e003084 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
EULAR
01.07.2023
BMJ Publishing Group LTD BMJ Publishing Group |
Series | Original research |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.MethodsConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.Results362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.ConclusionThe performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. |
---|---|
AbstractList | To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.OBJECTIVESTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.METHODSConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.RESULTS362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.CONCLUSIONThe performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models. 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal. The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.Methods Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.Results 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.Conclusion The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.MethodsConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.Results362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.ConclusionThe performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. |
Author | Huang, Can Tian, Xinping Li, Mengtao Zeng, Xiaofeng Wang, Qian Qi, Wanting Zhao, Yan Zhou, Yangzhong Zhao, Jiuliang Zhao, Yuan |
AuthorAffiliation | Department of Rheumatology and Clinical Immunology , Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China |
AuthorAffiliation_xml | – name: Department of Rheumatology and Clinical Immunology , Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China |
Author_xml | – sequence: 1 givenname: Yuan orcidid: 0000-0002-9405-6800 surname: Zhao fullname: Zhao, Yuan organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 2 givenname: Can surname: Huang fullname: Huang, Can organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 3 givenname: Wanting surname: Qi fullname: Qi, Wanting organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 4 givenname: Yangzhong surname: Zhou fullname: Zhou, Yangzhong organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 5 givenname: Jiuliang surname: Zhao fullname: Zhao, Jiuliang email: zjlpumc@sina.com organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 6 givenname: Qian surname: Wang fullname: Wang, Qian organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 7 givenname: Xinping orcidid: 0000-0002-1511-7952 surname: Tian fullname: Tian, Xinping organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 8 givenname: Mengtao orcidid: 0000-0003-4252-2889 surname: Li fullname: Li, Mengtao email: mengtao.li@cstar.org.cn organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 9 givenname: Yan surname: Zhao fullname: Zhao, Yan organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China – sequence: 10 givenname: Xiaofeng surname: Zeng fullname: Zeng, Xiaofeng organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37507205$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstrFTEUxgep2Fr7FwgScOPm2rwmubMSKT4KBTfqNmSSk95cZpIxmVvouv-45z6qbRdd5EHyfT--5JzXzVHKCZrmLaMfGRPqvIw-T5AWnHKxoFTQpXzRnHDaqkXbCXH0YH_cnNW6ppQyKYRm4lVzLHRLNQpOmrvfdojezjEnkgOZVwWATAV8dLuzMXsYKgm5bO_y2OcaKyngNqVAckBiIjbNcVrlimOIU_Sk3iaPWgQhGNJcSW8reII8i3BUAtJvgLi8ymV-07wMdqhwdlhPm19fv_y8-L64-vHt8uLz1aJvJZ1xxpf30roQaBsUV0oEtuSt73xwXDHLuLaSgnZBBCsE41aFIAR4DiCpF6fN5Z7rs12bqcTRlluTbTS7g1yujS1zdAOYloVegaatdGhlckm17xkPnQ5OB9oj69OeNW36EbzDVxY7PII-vklxZa7zjWFULLWSCgkfDoSS_2ygzmaM1cEw2AR5Uw1fSkk73nUdSt8_ka7zpiT8q61KUK1UR1H17mGkf1nui42Cbi9wWIJaIBgX513pMWEcMJrZ9pY59JbZ9pbZ9xZ6xRPvPf551_ne1Y_r_5mfc_wFV7_m-A |
CitedBy_id | crossref_primary_10_1515_cclm_2024_0114 crossref_primary_10_1016_j_lpmfor_2024_01_017 crossref_primary_10_18273_revmed_v37n2_2024006 |
Cites_doi | 10.1016/j.autrev.2022.103208 10.1016/j.atherosclerosis.2018.09.010 10.1177/0961203307081847 10.1093/rheumatology/keu307 10.1016/j.thromres.2020.10.010 10.1007/s11239-020-02195-4 10.1136/bmjopen-2020-045672 10.1161/CIRCULATIONAHA.107.699579 10.1111/ene.13499 10.1002/art.21149 10.1093/ckj/sfaa188 10.1182/blood-2017-09-805689 10.1093/rheumatology/kes388 10.1111/j.1538-7836.2010.04044.x 10.3389/fimmu.2022.843718 10.1177/0961203320916527 10.1093/rheumatology/41.8.924 10.1136/annrheumdis-2013-204838 10.1016/j.disamonth.2005.02.003 10.1177/0961203317703493 10.1177/0961203320960814 10.1093/rheumatology/kex466 10.1111/j.1538-7836.2006.01753.x 10.1186/s13075-021-02515-w 10.1016/j.semarthrit.2019.04.009 10.1111/1471-0528.15469 10.3389/fimmu.2021.648881 10.1093/rheumatology/kev238 10.1016/s0037-1963(01)90094-0 10.1111/jth.15047 10.1111/bjh.17388 10.1160/TH15-04-0330 10.1016/S0037-1963(01)90094-0 |
ContentType | Journal Article |
Copyright | Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 |
Copyright_xml | – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 |
DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU DWQXO FYUFA GHDGH K9. PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1136/rmdopen-2023-003084 |
DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central BMJ Journals ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition BMJ Journals ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2056-5933 |
ExternalDocumentID | oai_doaj_org_article_51fb6e7054ce4014807db12f97fc7f0b PMC10387646 37507205 10_1136_rmdopen_2023_003084 rmdopen |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) grantid: 2021-I2M-1-005 – fundername: Municipal College Students’ Scientific Research Innovation Program of Beijing grantid: S202110023033 – fundername: the Chinese National Key Technology R&D Program, Ministry of Science and Technology grantid: 2021YFC2501305 – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-A-008; 2022-PUMCH-A-038 – fundername: Beijing Municipal Science & Technology Commission grantid: Z201100005520022; Z201100005520023; Z201100005520025; Z201100005520026; Z201100005520027 – fundername: ; grantid: 2021YFC2501305 – fundername: ; grantid: 2022-PUMCH-A-008; 2022-PUMCH-A-038 – fundername: ; grantid: S202110023033 – fundername: ; grantid: Z201100005520022; Z201100005520023; Z201100005520025; Z201100005520026; Z201100005520027 – fundername: ; grantid: 2021-I2M-1-005 |
GroupedDBID | 53G 5VS 7X7 8FI 8FJ 9YT ABUWG ACMMV ADBBV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV BENPR BTFSW BTHHO CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE HZ~ KQ8 M48 M~E O9- OK1 PGMZT PHGZT PIMPY PQQKQ PROAC RHI RMJ RPM UKHRP AAYXX ADRAZ CITATION PHGZM PJZUB PPXIY CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-b540t-b5113b4acff05f62663f1825d9dfc261a127a40e7cf3fa3312a6ff33ed2ee40d3 |
IEDL.DBID | M48 |
ISSN | 2056-5933 |
IngestDate | Wed Aug 27 01:31:53 EDT 2025 Thu Aug 21 18:42:24 EDT 2025 Fri Jul 11 01:59:17 EDT 2025 Fri Jul 25 05:37:25 EDT 2025 Thu Apr 03 07:00:46 EDT 2025 Thu Aug 21 00:32:07 EDT 2025 Thu Apr 24 22:56:28 EDT 2025 Thu Apr 24 22:49:55 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Antiphospholipid Syndrome Recurrence Thrombosis Lupus Erythematosus, Systemic |
Language | English |
License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b540t-b5113b4acff05f62663f1825d9dfc261a127a40e7cf3fa3312a6ff33ed2ee40d3 |
Notes | Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 YZ and CH are joint first authors. |
ORCID | 0000-0002-1511-7952 0000-0002-9405-6800 0000-0003-4252-2889 |
OpenAccessLink | https://rmdopen.bmj.com/content/9/3/e003084.full |
PMID | 37507205 |
PQID | 2843076690 |
PQPubID | 2041888 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_51fb6e7054ce4014807db12f97fc7f0b pubmedcentral_primary_oai_pubmedcentral_nih_gov_10387646 proquest_miscellaneous_2844092999 proquest_journals_2843076690 pubmed_primary_37507205 crossref_citationtrail_10_1136_rmdopen_2023_003084 crossref_primary_10_1136_rmdopen_2023_003084 bmj_journals_10_1136_rmdopen_2023_003084 |
PublicationCentury | 2000 |
PublicationDate | 2023-07-01 |
PublicationDateYYYYMMDD | 2023-07-01 |
PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
PublicationSeriesTitle | Original research |
PublicationTitle | Rheumatic & musculoskeletal diseases open |
PublicationTitleAbbrev | RMD Open |
PublicationTitleAlternate | RMD Open |
PublicationYear | 2023 |
Publisher | EULAR BMJ Publishing Group LTD BMJ Publishing Group |
Publisher_xml | – name: EULAR – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
References | Fernandez Mosteirin, Saez Comet, Salvador Osuna (R13) 2017; 26 de Jesús, Sciascia, Andrade (R9) 2019; 126 Barbar, Noventa, Rossetto (R14) 2010; 8 Caprini, Arcelus, Reyna (R16) 2001; 38 Orsi, Lijfering, Geersing (R28) 2021; 193 Sciascia, Sanna, Murru (R4) 2015; 54 Uludağ, Bektaş, Çene (R7) 2021; 51 Jiang, Wang, Jiang (R30) 2021; 23 Miyakis, Lockshin, Atsumi (R17) 2006; 4 Pandor, Tonkins, Goodacre (R24) 2021; 11 Caprini (R15) 2005; 51 Barilaro, Coloma-Bazan, Chacur (R1) 2022; 21 Tang, Hu (R22) 2015; 114 Ramspek, Jager, Dekker (R23) 2021; 14 Sciascia, Sanna, Murru (R3) 2013; 52 Devreese, de Groot, de Laat (R20) 2020; 18 Calvo-Alén, Toloza, Fernández (R29) 2005; 52 Zuily, de Laat, Mohamed (R10) 2015; 54 de Souza, Silva, de Carvalho (R25) 2007; 16 Sayar, Moll, Isenberg (R19) 2021; 198 Erkan, Yazici, Peterson (R26) 2002; 41 Radin, Schreiber, Cecchi (R5) 2018; 25 Cervera, Serrano, Pons-Estel (R2) 2015; 74 Radin, Sciascia, Erkan (R6) 2019; 49 Kearon, Parpia, Spencer (R32) 2018; 131 Di Minno, Scalera, Tufano (R8) 2018; 278 Niznik, Rapoport, Avnery (R12) 2022; 13 Hu, Li, Xie (R21) 2021; 12 Sciascia, Radin, Sanna (R27) 2018; 57 Garcia, Velloso, Martire (R31) 2020; 29 Nascimento, Radin, Gândara (R11) 2020; 29 D’Agostino, Vasan, Pencina (R18) 2008; 117 Nascimento (2025081710461729000_9.3.e003084.11) 2020; 29 Fernandez Mosteirin (2025081710461729000_9.3.e003084.13) 2017; 26 Uludağ (2025081710461729000_9.3.e003084.7) 2021; 51 2025081710461729000_9.3.e003084.28 2025081710461729000_9.3.e003084.29 Caprini (2025081710461729000_9.3.e003084.16) 2001; 38 2025081710461729000_9.3.e003084.26 Garcia (2025081710461729000_9.3.e003084.31) 2020; 29 2025081710461729000_9.3.e003084.25 2025081710461729000_9.3.e003084.23 Niznik (2025081710461729000_9.3.e003084.12) 2022; 13 Radin (2025081710461729000_9.3.e003084.5) 2018; 25 Sciascia (2025081710461729000_9.3.e003084.27) 2018; 57 Hu (2025081710461729000_9.3.e003084.21) 2021; 12 Tang (2025081710461729000_9.3.e003084.22) 2015; 114 Devreese (2025081710461729000_9.3.e003084.20) 2020; 18 2025081710461729000_9.3.e003084.17 2025081710461729000_9.3.e003084.18 2025081710461729000_9.3.e003084.15 Sayar (2025081710461729000_9.3.e003084.19) 2021; 198 2025081710461729000_9.3.e003084.3 2025081710461729000_9.3.e003084.2 2025081710461729000_9.3.e003084.10 2025081710461729000_9.3.e003084.32 2025081710461729000_9.3.e003084.30 2025081710461729000_9.3.e003084.14 Di Minno (2025081710461729000_9.3.e003084.8) 2018; 278 Pandor (2025081710461729000_9.3.e003084.24) 2021; 11 Barilaro (2025081710461729000_9.3.e003084.1) 2022; 21 2025081710461729000_9.3.e003084.6 de Jesús (2025081710461729000_9.3.e003084.9) 2019; 126 2025081710461729000_9.3.e003084.4 |
References_xml | – volume: 21 start-page: 103208 year: 2022 ident: R1 article-title: Persistence of Antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2022.103208 – volume: 278 start-page: 60 year: 2018 ident: R8 article-title: The Association of adjusted global Antiphospholipid syndrome score (aGAPSS) with cardiovascular disease in subjects with Antiphospholipid antibodies publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.09.010 – volume: 16 start-page: 782 year: 2007 ident: R25 article-title: Impact of hypertension and Hyperhomocysteinemia on arterial thrombosis in primary Antiphospholipid syndrome publication-title: Lupus doi: 10.1177/0961203307081847 – volume: 54 start-page: 134 year: 2015 ident: R4 article-title: The global anti-phospholipid syndrome score in primary APS publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keu307 – volume: 198 start-page: 213 year: 2021 ident: R19 article-title: Thrombotic Antiphospholipid syndrome: A practical guide to diagnosis and management publication-title: Thromb Res doi: 10.1016/j.thromres.2020.10.010 – volume: 51 start-page: 466 year: 2021 ident: R7 article-title: Validation of the adjusted global Antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-020-02195-4 – volume: 11 year: 2021 ident: R24 article-title: Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review publication-title: BMJ Open doi: 10.1136/bmjopen-2020-045672 – volume: 117 start-page: 743 year: 2008 ident: R18 article-title: General cardiovascular risk profile for use in primary care: the Framingham heart study publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.699579 – volume: 25 start-page: 320 year: 2018 ident: R5 article-title: The risk of ischaemic stroke in primary Antiphospholipid syndrome patients: a prospective study publication-title: Eur J Neurol doi: 10.1111/ene.13499 – volume: 52 start-page: 2060 year: 2005 ident: R29 article-title: Systemic lupus erythematosus in a Multiethnic US cohort (LUMINA). XXV. smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients publication-title: Arthritis Rheum doi: 10.1002/art.21149 – volume: 14 start-page: 49 year: 2021 ident: R23 article-title: External validation of Prognostic models: what, Why, how, when and where publication-title: Clin Kidney J doi: 10.1093/ckj/sfaa188 – volume: 131 start-page: 2151 year: 2018 ident: R32 article-title: Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism publication-title: Blood doi: 10.1182/blood-2017-09-805689 – volume: 52 start-page: 1397 year: 2013 ident: R3 article-title: GAPSS: the global anti-phospholipid syndrome score publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kes388 – volume: 8 start-page: 2450 year: 2010 ident: R14 article-title: A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2010.04044.x – volume: 13 year: 2022 ident: R12 article-title: Patterns of recurrent thrombosis in primary Antiphospholipid syndrome-multicenter, real-life long-term follow-up publication-title: Front Immunol doi: 10.3389/fimmu.2022.843718 – volume: 29 start-page: 676 year: 2020 ident: R11 article-title: Global Antiphospholipid syndrome score and anti-Ss2-glycoprotein I domain I for thrombotic risk stratification in Antiphospholipid syndrome: A four-year prospective study publication-title: Lupus doi: 10.1177/0961203320916527 – volume: 41 start-page: 924 year: 2002 ident: R26 article-title: A cross-sectional study of clinical thrombotic risk factors and preventive treatments in Antiphospholipid syndrome publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/41.8.924 – volume: 74 start-page: 1011 year: 2015 ident: R2 article-title: Morbidity and mortality in the Antiphospholipid syndrome during a 10-year period: a Multicentre prospective study of 1000 patients publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-204838 – volume: 51 start-page: 70 year: 2005 ident: R15 article-title: Thrombosis risk assessment as a guide to quality patient care publication-title: Dis Mon doi: 10.1016/j.disamonth.2005.02.003 – volume: 26 start-page: 1328 year: 2017 ident: R13 article-title: Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting publication-title: Lupus doi: 10.1177/0961203317703493 – volume: 29 start-page: 1866 year: 2020 ident: R31 article-title: Validation of the adjusted global Antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina publication-title: Lupus doi: 10.1177/0961203320960814 – volume: 57 start-page: 661 year: 2018 ident: R27 article-title: Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kex466 – volume: 4 start-page: 295 year: 2006 ident: R17 article-title: International consensus statement on an update of the classification criteria for definite Antiphospholipid syndrome (APS) publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 23 year: 2021 ident: R30 article-title: Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric Antiphospholipid syndrome: a prospective cohort study publication-title: Arthritis Res Ther doi: 10.1186/s13075-021-02515-w – volume: 49 start-page: 464 year: 2019 ident: R6 article-title: The adjusted global Antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2019.04.009 – volume: 126 start-page: 656 year: 2019 ident: R9 article-title: Factors associated with first thrombosis in patients presenting with obstetric Antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and repository: a retrospective study publication-title: BJOG doi: 10.1111/1471-0528.15469 – volume: 12 start-page: 648881 year: 2021 ident: R21 article-title: Comparison of different test systems for the detection of Antiphospholipid antibodies in a Chinese cohort publication-title: Front Immunol doi: 10.3389/fimmu.2021.648881 – volume: 54 start-page: 2071 year: 2015 ident: R10 article-title: Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective Multicentre cohort study publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kev238 – volume: 38 start-page: 12 issue: 2 Suppl 5 year: 2001 ident: R16 article-title: Effective risk stratification of surgical and Nonsurgical patients for venous thromboembolic disease publication-title: Semin Hematol doi: 10.1016/s0037-1963(01)90094-0 – volume: 18 start-page: 2828 year: 2020 ident: R20 article-title: Guidance from the scientific and standardization Committee for lupus anticoagulant/Antiphospholipid antibodies of the International society on thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation publication-title: Journal of Thrombosis and Haemostasis doi: 10.1111/jth.15047 – volume: 193 start-page: 1194 year: 2021 ident: R28 article-title: Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study publication-title: Br J Haematol doi: 10.1111/bjh.17388 – volume: 114 start-page: 901 year: 2015 ident: R22 article-title: Ethnic diversity in the Genetics of venous thromboembolism publication-title: Thromb Haemost doi: 10.1160/TH15-04-0330 – ident: 2025081710461729000_9.3.e003084.32 doi: 10.1182/blood-2017-09-805689 – volume: 126 start-page: 656 year: 2019 ident: 2025081710461729000_9.3.e003084.9 article-title: Factors associated with first thrombosis in patients presenting with obstetric Antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and repository: a retrospective study publication-title: BJOG doi: 10.1111/1471-0528.15469 – ident: 2025081710461729000_9.3.e003084.10 doi: 10.1093/rheumatology/kev238 – volume: 57 start-page: 661 year: 2018 ident: 2025081710461729000_9.3.e003084.27 article-title: Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kex466 – ident: 2025081710461729000_9.3.e003084.4 doi: 10.1093/rheumatology/keu307 – volume: 51 start-page: 466 year: 2021 ident: 2025081710461729000_9.3.e003084.7 article-title: Validation of the adjusted global Antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-020-02195-4 – ident: 2025081710461729000_9.3.e003084.26 doi: 10.1093/rheumatology/41.8.924 – ident: 2025081710461729000_9.3.e003084.28 doi: 10.1111/bjh.17388 – ident: 2025081710461729000_9.3.e003084.18 doi: 10.1161/CIRCULATIONAHA.107.699579 – volume: 21 start-page: 103208 year: 2022 ident: 2025081710461729000_9.3.e003084.1 article-title: Persistence of Antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2022.103208 – volume: 25 start-page: 320 year: 2018 ident: 2025081710461729000_9.3.e003084.5 article-title: The risk of ischaemic stroke in primary Antiphospholipid syndrome patients: a prospective study publication-title: Eur J Neurol doi: 10.1111/ene.13499 – ident: 2025081710461729000_9.3.e003084.14 doi: 10.1111/j.1538-7836.2010.04044.x – volume: 29 start-page: 1866 year: 2020 ident: 2025081710461729000_9.3.e003084.31 article-title: Validation of the adjusted global Antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina publication-title: Lupus doi: 10.1177/0961203320960814 – ident: 2025081710461729000_9.3.e003084.6 doi: 10.1016/j.semarthrit.2019.04.009 – ident: 2025081710461729000_9.3.e003084.2 doi: 10.1136/annrheumdis-2013-204838 – volume: 29 start-page: 676 year: 2020 ident: 2025081710461729000_9.3.e003084.11 article-title: Global Antiphospholipid syndrome score and anti-Ss2-glycoprotein I domain I for thrombotic risk stratification in Antiphospholipid syndrome: A four-year prospective study publication-title: Lupus doi: 10.1177/0961203320916527 – ident: 2025081710461729000_9.3.e003084.15 doi: 10.1016/j.disamonth.2005.02.003 – ident: 2025081710461729000_9.3.e003084.25 doi: 10.1177/0961203307081847 – volume: 12 start-page: 648881 year: 2021 ident: 2025081710461729000_9.3.e003084.21 article-title: Comparison of different test systems for the detection of Antiphospholipid antibodies in a Chinese cohort publication-title: Front Immunol doi: 10.3389/fimmu.2021.648881 – volume: 11 year: 2021 ident: 2025081710461729000_9.3.e003084.24 article-title: Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review publication-title: BMJ Open doi: 10.1136/bmjopen-2020-045672 – volume: 26 start-page: 1328 year: 2017 ident: 2025081710461729000_9.3.e003084.13 article-title: Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting publication-title: Lupus doi: 10.1177/0961203317703493 – volume: 13 year: 2022 ident: 2025081710461729000_9.3.e003084.12 article-title: Patterns of recurrent thrombosis in primary Antiphospholipid syndrome-multicenter, real-life long-term follow-up publication-title: Front Immunol doi: 10.3389/fimmu.2022.843718 – volume: 18 start-page: 2828 year: 2020 ident: 2025081710461729000_9.3.e003084.20 article-title: Guidance from the scientific and standardization Committee for lupus anticoagulant/Antiphospholipid antibodies of the International society on thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation publication-title: Journal of Thrombosis and Haemostasis doi: 10.1111/jth.15047 – volume: 278 start-page: 60 year: 2018 ident: 2025081710461729000_9.3.e003084.8 article-title: The Association of adjusted global Antiphospholipid syndrome score (aGAPSS) with cardiovascular disease in subjects with Antiphospholipid antibodies publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.09.010 – volume: 38 start-page: 12 issue: 2 Suppl 5 year: 2001 ident: 2025081710461729000_9.3.e003084.16 article-title: Effective risk stratification of surgical and Nonsurgical patients for venous thromboembolic disease publication-title: Semin Hematol doi: 10.1016/S0037-1963(01)90094-0 – ident: 2025081710461729000_9.3.e003084.23 doi: 10.1093/ckj/sfaa188 – volume: 198 start-page: 213 year: 2021 ident: 2025081710461729000_9.3.e003084.19 article-title: Thrombotic Antiphospholipid syndrome: A practical guide to diagnosis and management publication-title: Thromb Res doi: 10.1016/j.thromres.2020.10.010 – ident: 2025081710461729000_9.3.e003084.30 doi: 10.1186/s13075-021-02515-w – ident: 2025081710461729000_9.3.e003084.17 doi: 10.1111/j.1538-7836.2006.01753.x – ident: 2025081710461729000_9.3.e003084.3 doi: 10.1093/rheumatology/kes388 – ident: 2025081710461729000_9.3.e003084.29 doi: 10.1002/art.21149 – volume: 114 start-page: 901 year: 2015 ident: 2025081710461729000_9.3.e003084.22 article-title: Ethnic diversity in the Genetics of venous thromboembolism publication-title: Thromb Haemost doi: 10.1160/TH15-04-0330 |
SSID | ssj0001433713 |
Score | 2.2390263 |
Snippet | ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict... To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis... Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict... |
SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e003084 |
SubjectTerms | Adult Anemia Antibodies Anticoagulants Antiphospholipid Syndrome Antiphospholipid Syndrome - complications Antiphospholipid Syndrome - diagnosis Autoimmune diseases Autoimmunity Calibration Female Heart attacks Humans Hypertension Ischemia Lupus Lupus Erythematosus, Systemic Male Medical imaging Medical prognosis Middle Aged Morbidity Pregnancy Prospective Studies Pulmonary embolisms Recurrence Regression analysis Risk Assessment Thrombocytopenia Thromboembolism Thrombosis Thrombosis - diagnosis Thrombosis - epidemiology Thrombosis - etiology Transient ischemic attack Venous Thrombosis - diagnosis Venous Thrombosis - epidemiology Venous Thrombosis - etiology Young Adult |
SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB61Rap6QbxJKchIHDiQbhI79voIiKpCKqcWlVPkODYN6iarJP0F_PHOOMmWRajisKtV7Mwm88jM2JlvAN5pqbTXvIqNzzBBWS4F2py1-CunTS_BuaEC57Nv8vRCfL3ML3cgmWthulVFbaOOy9WvsaKBMJqaYaEXfOECuIo4poXpXXhArUlIj_WP87tVFSSOadcEL5RyOROMqU14PBI4gH2OjlJl1LNuF_9pyycF6P5_xZt_vzb5hx86eQQPpwCSfRwl_hh2XPME9s-mLfKn8Ps7RtZjoyTWejagrBxbdzQejoXWNz3DWJXG2lXZ9nXPOlp2D4V_rG4YcrteX7U9fq7rdV2xGdeATTCsPSPvVzGkZ5B4O9drMuq32w3P4OLky_nn03jqtBCXGLEN-I28KoWx3ie5xxxHco-JR17pylvMsUyaKSMSp6zn3nCeZkZ6z7mrMudEUvHnsNe0jXsJTNtUWGkymRstqMZLJdI6oZFtCc-XPIL3yPFispS-CEkIl8Ukp4LkVIxyiiCbxVLYCbGcGmdc33_Sh81J6xGw4_7pn0jem6mEth0OtN3PYjLeIk99KZ3C6BbvhJZgE1WVaea18lb5pIzgaNaWuxtDv4_PTyl1EsHbzTAaL-3ImMa1N2EO5tcYEegIXozKtbmSWUUjWG6p3dalbo809VUACCfQeyWFPPx_Xr-Cg9FC6EXkI9gbuhv3GsOtoXwTLOwWNFUoqg priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhAXxJtAQUbiwIGoSezY6yMgqgqpnCjqLXL8UIO6ySpJfwF_nBnHu-wiVC4cEkWxkzjz8Mz48Q3AWy2VDpq73IQKA5TVSqDOWYtXNU16Cc4NbXA-_yrPLsSXy_pyL9UXrQlb4IEXwp3UZWilV-hZWC9o-KtQri2roFWwKhQt9b5o8_aCqTi6gh_B8CvBDJVcnoxrR_mockoXnkeUFoHmpF3_ODBIEbf_b87mn2sm94zQ6QO4n7xH9mFp9UO44_tHcPc8zY8_hp_f0a1esiSxIbAZGeXZZqTyeC_mvZkYOqpUNqzbYeomNtKYe9z1x7qeIam7zdUw4XHdbTrHtqAGLGGwToxMn2P4PoMvH7abNRkl2x3nJ3Bx-vnbp7M8pVnIW3TXZjwjgVphbAhFHTDAkTxg1FE77YLFAMuUlTKi8MoGHgznZWVkCJx7V3lkieNP4agfev8cmLalsNJUsjZa0AYvVUhkm0ayFbxe8QzeIcWbpCZTEyMQLpvEnIaY0yzMyaDasqWxCa6csmZc3_7Q-91DmwWt4_bqH4nfu6oEtR1voAA2SQCbfwlgBsdbafn9Y2j0sfOUUhcZvNkVo-bSdIzp_XAT62Bwje6AzuDZIly7lnB05FRV1BmsDsTuoKmHJX13FdHBCfFeSSFf_I-fewn3FoWh9cnHcDSPN_4VemFz-zoq3C9OUjIa priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxJvAgozEgQPRJrFjNycEiNUKaTmxqLfI8YPNahuHJPsL-OPMOE5LEeqhVRU7qeOZsb8Z298Q8rYSsnIVM6lyBTgoqxUHm9MafpW46MUZU3jA-fybOLvgX9flOgbcxritchkTw0BtvMYY-QkMo6COApy5D_2vFLNG4epqTKFxm9xB6jLUarmWuxgL_BU4YZFsKGfiZNgYzEqVYtLwNHC1cJhUms3V3rQU2Pv_Bzn_3Tn511R0-oDcjxiSfpyF_pDcst0jcvc8rpI_Jr9_ALiecyVR7-gE4rK0H7A8XAvZb0YKcBXL_KbxYzvSASPv4ewfbTsKHd72l36Ez3Xbt4Yu1AY0MrGOFCdAQ-F5Ch7ulyObFFPuDtMTcnH65fvnszQmW0gbAG0TfEMHNVxp57LSgZsjmAPfozSVcRrcLJUXUvHMSu2YU4zlhRLOMWZNYS3PDHtKjjrf2eeEVjrnWqhClKrieMxLZkJbXkG3ZaxcsYS8gx6vo7GMdfBDmKijcGoUTj0LJyHFIpZaR9JyzJ1xffim99ub-pmz43D1TyjvbVUk3A4X_PCzjvZbl7lrhJUAcOFNMAqbSdPkhauk09JlTUKOF23ZvdhOZxPyZlsM9ouLMqqz_ibUARcbQEGVkGezcm1bwgDOySIrE7LaU7u9pu6XdO1l4AhH3nspuHhxuF0vyb3ZFHD_8TE5moYb-wpQ1tS8Dqb0BxoUKZA priority: 102 providerName: ProQuest |
Title | Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
URI | https://rmdopen.bmj.com/content/9/3/e003084.full https://www.ncbi.nlm.nih.gov/pubmed/37507205 https://www.proquest.com/docview/2843076690 https://www.proquest.com/docview/2844092999 https://pubmed.ncbi.nlm.nih.gov/PMC10387646 https://doaj.org/article/51fb6e7054ce4014807db12f97fc7f0b |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-tmzTtBfFNxqiMxAMPFJLYsesHhLZp04TUCaF1Kk-Rk9gsqE26pJPgmX-cs-MUirY9NK3ijya-u9ydHf9-AG8kF9JIWoyUiTFBGY8Z2lye46_ELnoxSpXd4Dw552dT9nmWzLagZ0X1A9jemtpZPqlpM3__8_rXJzT4j56R5EOzKGzRyDKBjxwACxvADromYSkNJj7ed5Mu-N-YlXn0oTva7sEuRT8qYktpN8gWPzZclkP2vy0c_f-tyn_c1OlDeODjS3LYKcQj2NLVY9id-BX0J_D7EgPvjkeJ1IasUJSaLBtb7s45ZpyWYChry-pFVrdlSxo7K-_2BZKyIiiMcnlVt_iZl8uyID3sAfEorS2xzrEg2J_Czut-OyexdLzN6ilMT08ujs9GnohhlGFAt8IjjlXGVG5MmBhMgTg1mJckhSxMjimYimKhWKhFbqhRlEax4sZQqotYaxYW9BlsV3WlXwCRecRyrmKeKMnsFjAR8lwzicMW0mRMA3iLI572epC6HIXy1MsptXJKOzkFEPdiSXMPaG55Neb3N3q3brTs8Dzur35k5b2uasG43Ym6-Z56206TyGRcCwx-8U7sDG0oiiyKjRQmFybMAjjoteXvjWFYgI9XzmUYwOt1Mdq2XbBRla5vXB1MvzFgkAE875RrfSW9igYw3lC7jUvdLKnKK4cfbjHxBWd8_85OX8JeZxD2teQD2F41N_oVBl-rbAgDMRN4lN8uhrBzeDyZXOL30cn5l69DN6ExdCb3B09vNAw |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4lkCBYwEEgeiJrFjbw4I8aq2tNtTi_YWHMemQd0kJKkQZ_4Pv5EZJ9llEdpbD4mi2LHszOsbP2YIeZ4ImdiE5b6yETgokwkHmdManmJc9OKMKTzgPDsW01P-aR7Pt8jv8SwMbqscdaJT1HmlcY58D9QosKMAZ-5N_d3HrFG4ujqm0OjZ4tD8_AEuW_v64APQ90UU7X88eT_1h6wCfgbopIN7GLKMK21tEFvA84JZANlxnuRWgz-hwkgqHhipLbOKsTBSwlrGTB4Zw4OcQbtXyFUwvAE6e3IuV3M6MDRw-obgRiETe80ixyxYPiYp911sGA5GLFt8WzODLlvA_yDuvzs1_zJ9-7fIzQGz0rc9k90mW6a8Q67NhlX5u-TXZwDzfW4mWlnaAXsYWjdY7t65bDstBXiMZdUiq9qipQ3O9LuzhrQoKRC4qM-qFq7zoi5yOoZSoEPk15aiwc0ptKeg8Wo8IkoxxW_T3SOnl0KG-2S7rErzgNBEh1wLFYlYJRyPlclAaMMT-G0BiyfMIy_hj6eDcLap83uYSAfipEictCeOR6KRLKkegqRjro7zzR-9Wn5U9zFCNld_h_ReVsUA3-5F1XxNB32RxqHNhJEAqGEkOOsbyDwLI5tIq6UNMo_sjtyyGthKRjzybFkM-gIXgVRpqgtXB1x6ACGJR3Z65lr2hAF8lFEQe2SyxnZrXV0vKYszF5Mc4-xLwcXDzf16Sq5PT2ZH6dHB8eEjcqMXC9z7vEu2u-bCPAaE12VPnFhR8uWy5fgPUHtnEw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVqq4IN6kFDASSByINokde3NAiNKuWkpXFaKot-A4Nk3VTZZkK8SZf8WvYyZxdlmE9tZDoih2LDvz8De2Z4aQF4mQiU1Y7isbgYEyGnGQOa3hKcZNL86YQgfn44k4OOUfzuKzDfK794XBY5W9TmwVdV5pXCMfghoFdhRgzA2tOxZxsjd-O_vuYwYp3Gnt02l0LHJkfv4A8615c7gHtH4ZReP9z-8PfJdhwM8AqczhHoYs40pbG8QWsL1gFgB3nCe51WBbqDCSigdGasusYiyMlLCWMZNHxvAgZ9DuDbIp0SoakM3d_cnJp-UKDwwUTEAX6ihkYlhPc8yJ5WPKcr-NFMNhSsumFyuTYps74H-A999zm39NhOPb5JZDsPRdx3J3yIYp75KtY7dHf4_8-gLQvsvURCtL58Ashs5qLG_ftbl3GgpgGcuqaVY1RUNrXPdvPQ9pUVIgdzE7rxq4LotZkdM-sAJ1cWAbitNvTqE9BY1XvcMoxYS_9fw-Ob0WQjwgg7IqzSNCEx1yLVQkYpVwdDKTgdCGJ_DbAhaPmEdewR9Pnag2aWsFMZE64qRInLQjjkeiniypdiHTMXPH5fqPXi8-mnURQ9ZX30V6L6piuO_2RVV_S532SOPQZsJIgNcwElwDDmSehZFNpNXSBplHdnpuWQ5sKTEeeb4oBu2BW0KqNNVVWwcMfIAkiUcedsy16AkDMCmjIPbIaIXtVrq6WlIW522Ecoy6LwUX2-v79YxsgQynHw8nR4_JzU4q8CD0DhnM6yvzBODePHvq5IqSr9ctyn8A7edsrg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+three+prediction+models+for+thrombosis+recurrence+in+antiphospholipid+syndrome+patients+based+on+a+prospective+cohort&rft.jtitle=Rheumatic+%26+musculoskeletal+diseases+open&rft.au=Zhao%2C+Yuan&rft.au=Huang%2C+Can&rft.au=Qi%2C+Wanting&rft.au=Zhou%2C+Yangzhong&rft.date=2023-07-01&rft.eissn=2056-5933&rft.volume=9&rft.issue=3&rft_id=info:doi/10.1136%2Frmdopen-2023-003084&rft_id=info%3Apmid%2F37507205&rft.externalDocID=37507205 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-5933&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-5933&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-5933&client=summon |